Rotavirus vaccine

Lai saņemtu informāciju par iepirkumiem e-pastā, piesakieties, spiežot uz "Saņemt iepirkumu informāciju" lapas lejasdaļā!

The Norwegian Institute of Public Health (NIPH) [Folkehelseinstituttet (FHI)] has implemented an open tender competition for the procurement of vaccine against rotavirus for the base vaccination of infants in the Norwegian child vaccination programme, starting up in Q1 2023. The scope of the procurement is estimated at a number of doses sufficient to fully immunise up to 65,000 infants in need in the Norwegian child vaccination programme per calendar year. The estimated total scope for the contract period, with the full extension of the contract period (option), is estimated to be up to approx. 260,000 full immunisations. FHI [NIPH] has awarded one contract to GlaxoSmithKline AS. The chosen vaccine is Rotarix, which is used for vaccination through a two-dose regimen. The procurement shall be implemented as an open tender contest in accordance with the Public Procurement Regulations Parts 1 and 3. The procurement shall be implemented electronically via the CTM-KGV portal (EU-Supply) and the tender notice is published in Doffin and TED.